Evidence map›Paper›PMID 22116611›Full record

ArticleJournal of molecular modeling2012

Structural determinants of imidacloprid-based nicotinic acetylcholine receptor inhibitors identified using 3D-QSAR, docking and molecular dynamics.

Qinfan Li, Xiangya Kong, Zhengtao Xiao, Lihui Zhang, Fangfang Wang, Hong Zhang, Yan Li, Yonghua Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular modeling, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Qinfan LiCollege of Veterinary Medicine, Northwest A & F University, Yangling, Shaanxi, China.
Xiangya Kong
Zhengtao Xiao
Lihui Zhang
Fangfang Wang
Hong Zhang
Yan Li
Yonghua Wang
Northwest A&F University · CNDalian University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nicotinic acetylcholine receptor (nAChR) is a target for insect-selective neonicotinoid insecticides (NNs), exemplified by imidacloprid (IMI). In the present study, 78 IMI derivatives reported as inhibitors of Drosophila melanogaster nAChR (Dm-nAChR) and Musca domestica nAChR (Md-nAChR) were used for three-dimensional quantitative structure-activity relationship (3D-QSAR) studies. Two optimal models with good predictive power were obtained: Q(2) = 0.64, R(2)(pred) = 0.72 for Dm-nAChR, and Q(2) = 0.63, R(2)(pred) = 0.62 for Md-nAChR. In addition, homology modeling, molecular dynamic (MD) simulation, and molecular docking also showed that amino acids located within loops A, C, D and E play key roles in the interaction of Dm-/Md-nAChR with NNs. This is highly consistent with the results of graphical analysis of 3D-QSAR contour plots. Mutation analysis also implicates the Y/S mutation within loop B as being associated closely with NN resistance in Drosophila and Musca. The results obtained lead to a better understanding not only of interactions between these antagonists and Dm-/Md-nAChR, but also of the essential features that should be considered when designing novel inhibitors with desired activities.

Indexed as

Models, MolecularAmino Acid SequenceAmino Acid SubstitutionAnimalsBinding SitesConserved SequenceHydrogen BondingHydrophobic and Hydrophilic InteractionsImidazolesInsecticidesInsect ProteinsMolecular Dynamics SimulationMolecular Sequence DataNeonicotinoidsNicotinic AntagonistsNitro CompoundsimidaclopridImidazolesInsecticidesInsect ProteinsNeonicotinoidsNicotinic AntagonistsNitro CompoundsReceptors, Nicotinic

Identifiers

PMID22116611
OpenAlexW2090310497

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.